Skip to content

The effect of hemoperfusion adsorption on the regulation of Th1/Th2 and Th17/Treg in cellular immunity and prognosis in patients with septic shock complicated with ARDS

The effect of hemoperfusion adsorption on the regulation of Th1/Th2 and Th17/Treg in cellular immunity and prognosis in patients with septic shock complicated with ARDS

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500108688
Enrollment
Unknown
Registered
2025-09-03
Start date
2025-09-15
Completion date
Unknown
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Septic shock

Interventions

CVVH :Continuous hemofiltration treatment
CVVH+HP group:Continuous hemofiltration treatment+Hemofiltration adsorption

Sponsors

Zhengzhou Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Septic shock: Complies with the standards of the Chinese Guidelines for Emergency Treatment of Sepsis/Septic Shock (2018); 2.ARDS: Conforms to the Berlin definition of ARDS in 2012.

Exclusion criteria

Exclusion criteria: 1. Having suffered from malignant tumors, blood or immune diseases within 6 months prior to hospitalization; 2. Those who have been treated with immunosuppressants or steroids for a long time or have received chemotherapy drugs; 3. Patients with a history of severe organ dysfunction; 4.Patients with hematological diseases complicated with severe bleeding tendencies; 5.Those with severe heart failure or severe arrhythmia who cannot tolerate cardiopulmonary bypass; 6. Patients in the terminal stage of various diseases or in an irreversible terminal state; 7.Pregnant women; 8.Participating in other research or unwilling to participate in this researcher; 9.Patients with incomplete data or those who fail to adhere to systematic treatment due to personal reasons. All patients' family members signed informed consent forms before treatment, and the treatment plans were approved by the hospital's ethics committee.

Design outcomes

Primary

MeasureTime frame
Survival ending;

Secondary

MeasureTime frame
Th1;Th2;Th17;Treg;

Countries

China

Contacts

Public ContactGao Yanqiu

Zhengzhou Central Hospital

drgaoyanqiu@126.com+86 136 7399 9263

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026